

Individual long-term mortality prediction following either coronary stenting or bypass surgery in patients with multivessel and/or unprotected left-main disease: An external validation of the SYNTAX score II model in the 1480 patients of BEST and PRECOMBAT randomized controlled trials

April 26 5:00-5:10 pm

Yoshinobu Onuma, MD, PhD
Erasmus MC, Rotterdam, The Netherlands

Yohei Sotomi, MD; Rafael Cavalcante, MD, PhD.;
David van Klaveren, MSc; Jung-Min Ahn, MD.; Cheol Whan Lee, MD;
Ewout W Steyerberg, PhD; Robbert J. de Winter, MD, PhD;
Joanna J. Wykrzykowska, MD, PhD;
Seung-Jung Park, MD, PhD.; Patrick W Serruys MD, PhD.

Background

- In patients with multivessel coronary disease and/or unprotected left main disease, the choice of the best revascularization strategy is not simple.
- The **SYNTAX score II** is a tool created using the predictors of 4 years mortality after both treatments in the landmark all-comers SYNTAX trial. It takes into account not only the **anatomic complexity of the disease (SYNTAX SCORE)**, but also **clinical co-morbidities** that were shown to impact mortality in that trial. This score provides an individualized estimation of long-term mortality after **both PCI and CABG**. This prediction model is already recommended for risk stratification in the European guidelines as class IIa.

European Heart Journal (2014) 35, 2541–2619
doi:10.1093/eurheartj/ehu278

ESC/EACTS GUIDELINES

2014 ESC/EACTS Guidelines on myocardial revascularization

The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)

Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Risk models to assess medium- to long-term (≥1 year) outcomes

Score	Development cohort	Patient inclusion	Coronary procedures	Number of variables		Outcomes	Recommendation		Validation studies	Calculation	Ref ¹
				Clinical	Anatomical		CABG	PCI			
SYNTAX II	1800 Multicentre	03/2005 – 04/2007	50% CABG, 50% PCI	6	11	4-year mortality	IIa B	IIa B	<5	–	25
CABG	Multicentre	01/2002	(i) CABG	23	2	>2 years	IIa B	–	<5	–	27
ASCERT PCI	204 DBI Multicentre	2004 – 2007	100% PCI	17	2	Mortality >1 year	–	IIa B	<5	–	28
LogitK Clinical SYNTAX	6 308 Multicentre	03/2005 – 04/2007	100% PCI	3	11	1-year MACE and mortality	–	IIa B	<5	–	24

ASCERT = American College of Cardiology Foundation–Society of Thoracic Surgeons Database Collaboration (ACCf–STS) on the comparative effectiveness of revascularization strategies; (i) CABG = (isolated) coronary artery bypass grafting; MACE = major adverse cardiac and cerebrovascular events; PCI = percutaneous coronary intervention; SYNTAX = syntax; – = not applicable.

SYNTAX Score II variables

SYNTAX Score II was developed by applying a Cox proportional hazards model to the results of SYNTAX trial obtaining a **combination of clinical and anatomical independent predictors of 4 years all-cause mortality:**

ANATOMICAL
SYNTAX SCORE

LM

AGE

Cr Clearance

LVEF

Gender

PVD

COPD

By: Ewout W. Steyerberg, PhD, Department of Public Health, Erasmus University Rotterdam, the Netherlands, and Prof. Frank E. Harrell Jr, PhD, Department of Health Evaluation Sciences, University of Virginia, Charlottesville, VA.



- ▶ [Author Biography](#)
- ▶ [Introduction](#)
- ▶ [Predictions from Statistical Models](#)
- ▶ [Insight from Statistical Models](#)
- ▶ [Ingredients of Statistical Models](#)
- ▶ [Theoretical Aspects of Predictive Modeling](#)
- ▶ [Central Concepts in Predictive Modeling](#)
- ▶ [Development of Regression Models](#)

Special Report

Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction

Nancy R. Cook, ScD


Abstra
test
non
indi
a bi
10-

“As novel risk factors are discovered, sole reliance on the c-statistic to evaluate their utility as risk predictors thus seems ill-advised...”

agnostic
l versus
stratify
xample,
timated
eatmen

DISCRIMINATION

C-Statistics (area under ROC curve)




$$\text{Sensitivity} = \frac{\text{True Positive}}{\text{True Positive} + \text{False Negative}}$$

$$\text{Specificity} = \frac{\text{True Negative}}{\text{True Negative} + \text{False Positive}}$$

Discrimination refers to the ability to distinguish high risk subjects from low risk subjects, and is commonly quantified by a measure of concordance, the c statistic. For binary outcomes, c is identical to the area under the receiver operating characteristic curve

Calibration

Calibration refer to whether the predicted probabilities agree with the observed probabilities.



“There is, in fact, a trade-off between discrimination and calibration and a model typically cannot be perfect in both.”

CALIBRATION Of SYNTAX SCORE II in the DELTA [LM] and CREDO KYOTO [3VD] registries

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II

Naam Ament*, David van Klaveren*, Ewout W Steyerberg, Elmoukhalib Malhi, Yoon-Hyung Park, Abdo Chahin, Arie Pieter Kappetein, Antonio Colombo, David P Holmes Jr, Michael Mack, Ted S Halperin, Waseem Chaudhry, Elizabeth S DeBorja, Yoshinobu Onuma, Wouter Angold-Korner, Hester M Goicoechea, Gerrit Anne van Es, Karthi D Sowkara, Francesco M Mohr, Patrick W Serruys



Circulation Journal
Official Journal of the Japanese Circulation Society
<http://www.j-circ.or.jp>

ORIGINAL ARTICLE
Ischemic Heart Disease


Predictive Performance of SYNTAX Score II in Patients With Left Main and Multivessel Coronary Artery Disease

— Analysis of CREDO-Kyoto Registry —

Carlos M. Campos, MD; David van Klaveren; Javaid Iqbal, MD, PhD; Yoshinobu Onuma, MD, PhD; Yao-Jun Zhang, MD, PhD; Hector M. Garcia-Garcia, MD, PhD; Marie-Angele Morel, BSc; Vasim Farooq, MD, PhD; Hiroki Shiomi, MD; Yutaka Furukawa, MD; Yoshihisa Nakagawa, MD; Kazushige Kadota, MD; Pedro A. Lemos, MD, PhD; Takeshi Kimura, MD; Ewout W. Steyerberg, PhD; Patrick W. Serruys, MD, PhD


DELTA registry

b) Validation Plot SYNTAX Score II: DELTA Registry




CREDO KYOTO registry

A PCI group



B CABG group



However, Syntax II has been never validated in the context of Randomized trial...

Methods

Largest East Asian RCTs

Our primary objective was to assess the prediction and discrimination performance of the **Syntax score II** for PCI and CABG to appropriately stratify the risk of all-cause mortality in patients with severe coronary artery disease from largest Asian RCTs: BEST and PRECOMBAT trials.

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease

Seung-Jung Park, M.D., Ph.D., Jung-Min Ahn, M.D., Young-Hak Kim, M.D., Duk-Woo Park, M.D., Sung-Cheol Yun, Ph.D., Jong-Young Lee, M.D., Soo-Jin Kang, M.D., Seung-Whan Lee, M.D., Cheol Whan Lee, M.D., Seong-Wook Park, M.D., Suk Jung Choo, M.D., Cheol Hyun Chung, M.D., Jae Won Lee, M.D., David J. Cohen, M.D., Alan C. Yeung, M.D., Seung Ho Hur, M.D., Ki Bae Seung, M.D., Tae Hoon Ahn, M.D., Hyuck Moon Kwon, M.D., Do-Sun Lim, M.D., Seung-Woon Rha, M.D., Myung-Ho Jeong, M.D., Bong-Ki Lee, M.D., Damras Tresukosol, M.D., Guo Sheng Fu, M.D., and Tiong Kiam Ong, M.D., for the BEST Trial Investigators*

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
© 2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER INC.

VOL. 63, NO. 20, 2015
ISSN 0735-1017/\$36.00
<http://dx.doi.org/10.1016/j.jacc.2015.02.038>

Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease 5-Year Outcomes of the PRECOMBAT Study

Jung-Min Ahn, MD,* Jae-Hyung Roh, MD,* Young-Hak Kim, MD,* Duk-Woo Park, MD,* Sung-Cheol Yun, PhD,† Pili Hyung Lee, MD,* Minsok Chang, MD,* Hyun Woo Park, MD,* Seung-Whan Lee, MD,* Cheol Whan Lee, MD,* Seong-Wook Park, MD,‡ Suk Jung Choo, MD,* CheolHyun Chung, MD,* JaeWon Lee, MD,* Do-Sun Lim, MD,§ Seung-Woon Rha, MD,|| Sang-Gon Lee, MD,|| Hyeon-Cheol Gwon, MD,* Hyo-Soo Kim, MD,* In-Ho Chae, MD,** Yangsoo Jang, MD,†† Myung-Ho Jeong, MD,|| Seung-Jea Tahk, MD,||§ Ki Bae Seung, MD,|| Seung-Jung Park, MD*

BEST trial

a randomized trial conducted at 27 sites in South Korea, China, Malaysia, and Thailand that included 880 patients with multivessel coronary artery disease

PRECOMBAT trial

a randomized trial conducted at 13 sites in Korea that included 600 patients with documented unprotected left main coronary artery (ULMCA) stenosis

Study Population

n = 1480

BEST n = 880

PRECOMBAT n = 600

Missing data

n = 106

BEST n = 12

PRECOMBAT n = 94

**Multiple imputation (5 times)
for Syntax II variables**

n = 1480


BEST n = 880

PRECOMBAT n = 600

Number of Missing Values

	PRECOMBAT (n=600)	BEST (n=880)
Syntax score	34	0
CrCl	19	12
LVEF	44	0
UPLMD	0	0
Age	0	0
Gender	0	0
PVD	0	0
COPD	0	0

Overall Summary of Missing Values



Validation for SYNTAX score II in BEST and PRECOMBAT trials

- ***Discrimination performance***

Receiver-operating characteristic (ROC) curve was used to compare the prognostic ability (discrimination performance) of SYNTAX score II to predict the rates of all-cause death in the whole population, UPLMD disease population, and multivessel disease population. Discrimination was studied with the **concordance (C) index**, which is identical to the area under the ROC curve. The C-index estimates the probability that, of two randomly chosen patients, the patient with the more favorable prognostic score will outlive the patient with the less favorable prognostic score, and ranges from 0.5 (no discrimination) to a theoretical maximum of 1.

- ***Calibration performance***

The calibration performance of the Syntax score II was evaluated using **Calibration plots** in the same populations. Calibration refers to the agreement between observed and predicted outcomes. The possible over- or underestimation of the predicted risks were graphically assessed with validation plots.

Results: Patient characteristics (1/3)

	CABG (n=742)	PCI (n=738)
Age (years)	65 [57-71]	64 [56-70]
Male gender, n (%)	556 (74.9)	532 (72.1)
Height (cm)	164 [158-169]	164 [158-169]
Bodyweight (kg)	65.7 [58.6-72.4]	65.7 [59.0-72.0]
SYNTAX Score II variables		
Anatomical SYNTAX Score	25 [18-31]	24 [18-30]
Creatinine clearance (ml/min)	73.0 [58.4-89.9]	72.3 [56.4-89.6]
UPLMD, n (%)	300 (40.4)	300 (40.7)
Left ventricular ejection fraction (%)	60 [57-65]	60 [57-65]
Chronic obstructive pulmonary disease, n (%)	16 (2.2)	14 (1.9)
Peripheral vascular disease, n (%)	19 (2.6)	30 (4.1)
Treatment recommendation by SYNTAX Score II		
PCI	17 (2.3)	33 (4.5)
Equipoise	474 (63.9)	489 (66.3)
CABG	251 (33.8)	216 (29.3)


Results: Patient characteristics (2/3)

	CABG (n=742)	PCI (n=738)
Clinical presentation *		
Silent myocardial ischemia, n (%)	74 (10.0)	84 (11.4)
Stable angina, n (%)	330 (44.7)	366 (49.7)
Unstable angina, n (%)	277 (37.5)	232 (31.5)
Unstable angina and recent acute myocardial infarction, n (%)	58 (7.8)	55 (7.5)
Hypertension, n (%)	456 (61.5)	452 (61.2)
Diabetes, n (%)	275 (37.1)	282 (38.2)
Current smoker, n (%)	172 (23.2)	177 (24.0)
Hypercholesterolemia, n (%)	342 (46.1)	366 (49.6)
Previous myocardial infarction, n (%)	48 (6.5)	38 (5.1)
Previous PCI, n (%)	76 (10.2)	68 (9.2)
Previous cerebrovascular accident, n (%) †	33 (7.5)	37 (8.4)
Proximal LAD disease, n (%) ‡	545 (73.5)	563 (76.3)
Median follow-up duration (days)	1800 [1428-1800]	1800 [1403-1800]

Results: Patient characteristics (3/3)

	CABG (n=742)	PCI (n=738)
Procedural data		
CABG		
Off-pump CABG, n (%) §	407 (65.1)	
Number of total conduit (n) §	3.0 [2.0-3.0]	
Number of arterial conduit (n) §	2.0 [1-3.0]	
Number of venous conduit (n) §	1.0 [0-1.0]	
Use of LIMA, n (%) ¶	612 (97.1)	
PCI		
Number of stents (n) #		3.0 [2.0-4.0]
Total stent length (mm) ††		74 [50-102]
Mean stent diameter (mm) #		3.2 [3.0-3.4]
Stent type, n (%)		
Sirolimus-eluting stent		300 (40.7)
Everolimus-eluting stent		438 (59.3)
Complete revascularization**	506 (70.6)	420 (57.5)

Calibration Plots at Cross-Validation of SYNTAX score II in the entire population



Calibration Plots at Cross-Validation of SYNTAX score II in subgroups


Whole population

PCI

CABG

A


n = 1480



B


n = 300

Left Main



C


n = 300



D


n = 438

Multi-vessel



E

n = 442



Overestimation of Mortality in high SxSII group

SYNTAX score II Predicted 4 years mortality

Summary

- **The validity of the recommendation for PCI or CABG by SYNTAX score II model was supported for patients with multivessel and/or unprotected left-main coronary artery disease.**
- **The SYNTAX II score model showed good calibration but only moderate discrimination for the individual prediction of 4 years all-cause mortality after PCI and CABG in this population.**
- **In the highest Syntax II quintiles there was overestimation of 4-year mortality.**

What is the potential cause of overestimation of mortality especially in high Syntax II score group ?

1. SYNTAX Score II was established in the SYNTAX trial using TAXUS stent, while in the validation population (PRECOMBAT and BEST) Cypher and Xience stent were used. Mortality rate in TAXUS > SES/EES ??

2. In highest Syntax Score II group, complete revascularization rate were less in PCI, which could confound mortality prediction

Stent type used in the three trials

	SYNTAX	PRECOMBAT	BEST
Stent type	TAXUS	CYPHER	XIENCE



Dangas et al. JACC Cardiovasc Interv 2013.
Kaul et al. N Engl J Med 2015.

Syntax II Score	CABG arm	PCI arm
1st quintile	74.20%	76.40%
2nd quintile	65.90%	64.30%
3rd quintile	70.30%	52%
4th quintile	67.70%	51.30%
5th quintile	74.70%	52.50%

NO CHANGE DECREASE


What is the potential cause of overestimation of mortality especially in high Syntax II score group ?

Gender effect may play a role...



What is the potential cause of overestimation of mortality especially in high Syntax II score group ?

Gender effects are different amongst SYNTAX, PRECOMBAT, and BEST trials



In the SYNTAX trial (A), female gender favors CABG compared to PCI, while in the PRECOMBAT (B), BEST (C), and their combined database (D), female gender favors PCI rather than CABG.

Conclusions

- **The SYNTAX score II has good calibration but only moderate discrimination ability for the 4 years mortality prediction after PCI and CABG in patients with multivessel and/or unprotected left-main disease in the populations as randomized for BEST and PRECOMBAT trials.**
- **This score provides an important tool to help guide the Heart Team decision-making process regarding the selection of the best revascularization strategy for this patient population.**
- **The observed heterogeneity of treatment effect in women warrants further investigations involving the global geometry.**



SYNTAX Score II Online calculator

The SYNTAX Score is a tool developed in connection with the SYNTAX Trial, a trial comparing PCI and Cardiac Surgery in complex, high-risk LM and/or 3VD patients. It is important to note that **the safety and effectiveness of drug-eluting stents have not been established in these high risk patients**, and physicians are strongly encouraged to review the indications, contraindications, warnings and instructions included in the products' Directions for Use.

The SYNTAX Score is not intended to provide medical advice or guidance as to appropriate treatment for individual patients. Risks and benefits should be carefully considered for each patient taking into account all available data and treatment options and physicians and other healthcare providers should always exercise their own clinical judgment for each patient's situation. To see the full SYNTAX Score and related materials, see

Coming soon !!!

Yes, I have fully read the Important Information above.

Proceed with SYNTAX Score I

Proceed with SYNTAX Score II

Close calculator

Thank You!



Volume 11 - Number 13 - April 2016 - ISSN: 1774-024X

EuroIntervention

CORONARY INTERVENTIONS

- 1457** Complex coronary Bifurcation lesions: RANdOmized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial
C. Dubois, T. Adriaenssens, et al
- 1468** Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry
A. Itiguez, G.W. Stone, et al
- 1475** Clinical outcomes following "off-label" versus "established" indications of bioresorbable scaffolds for the treatment of coronary artery disease in a real-world population
T. Miyazaki, A. Colombo, et al
- 1479** A novel approach to treat in-stent stenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold
P. Janshidi, F. Cuculi, et al
- 1487** Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAAYA study
M.M. Kok, M.J. Uerman, et al
- 1495** Does access to invasive examination and treatment influence socioeconomic differences in case fatality for patients admitted for the first time with non-ST-elevation myocardial infarction or unstable angina?
S. Mårtensson, M. Osler, et al
- 1503** Virtual reality training in coronary angiography and its transfer effect to real-life catheterisation lab
U.J. Jensen, P. Tornvall, et al

- 1511** A disaster never comes alone: total ostial occlusion of the left main coronary artery with an anomalous origin
P. Rodrigues, S. Torres, et al

INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE

- 1512** Left atrial appendage occlusion with the AMPLATZER Amulet device: an expert consensus step-by-step approach
A. Tzikas, H. Omran, et al
- 1522** The prognostic value of acute and chronic troponin elevation after transcatheter aortic valve implantation
J.M. Sinning, N. Werner, et al
- 1530** Emergency transcatheter aortic valve replacement in patients with cardiogenic shock due to acutely decompensated aortic stenosis
C. Frerker, K.H. Kuck, et al
- 1537** First-in-man report of residual "intra-clip" regurgitation between two MitraClips treated by AMPLATZER Vascular Plug II
M. Taramasso, F. Maisano, et al
- 1541** First transfemoral percutaneous edge-to-edge repair of the tricuspid valve using the MitraClip system
T. Wengenmayer, S. Grundmann, et al
- 1545** First Lotus aortic valve-in-valve implantation to treat degenerated Mitroflow bioprostheses
F. Castriota, A. Cremonesi, et al
- 1549** Direct Flow valve-in-valve implantation in a degenerated mitral bioprosthesis
G. Bruschi, F. De Marco, et al

AsiaIntervention

www.asiaintervention.org

Volume 2 - Number 1 - January 2016 - ISSN: 2426-3958

CORONARY INTERVENTIONS

- 19** Late angiographic and clinical outcomes of the novel BioMime™ sirolimus-eluting coronary stent with ultra-thin cobalt-chromium platform and biodegradable polymer for the treatment of diseased coronary vessels: results from the prospective, multicentre meriT-2 clinical trial
- 28** Impact of chronic lung disease after percutaneous coronary intervention in Japanese patients with acute coronary syndrome
- 36** Distribution characteristics of coronary calcification and its substantial impact on stent expansion: an optical coherence tomography study
- 44** Smooth arterial healing after paclitaxel-coated balloon angioplasty for in-stent stenosis assessed by optical frequency domain imaging
- 48** Mediastinal haematoma complicating percutaneous coronary intervention via the radial artery

INTERVENTIONS FOR STRUCTURAL HEART DISEASE AND HEART FAILURE

- 49** Comparison of aortic annulus dimensions between Japanese and European patients undergoing transcatheter aortic valve implantation as determined by multi-detector computed tomography: results from the OCEAN-TAVI and a European single-centre cohort
- 57** Combined percutaneous transvenous mitral commissurotomy and left atrial appendage closure as an alternative to anticoagulation for rheumatic atrial fibrillation

EDITORIAL

- 7** Evolution and current status of interventional cardiology in India
- 10** Tailoring TAVI in Asia: insights from MSCT
- 13** Opening the shell for better stent results

ASIA-PACIFIC HOTLINES AT TCT 2015

- 16** Asia-Pacific Hotlines at TCT 2015: a prospective randomised trial of paclitaxel-eluting vs. everolimus-eluting stents in diabetic patients with coronary artery disease (TUXEDO)
- 17** Asia-Pacific Hotlines at TCT 2015: bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease (ABSORB China Trial)
- 18** Asia-Pacific Hotlines at TCT 2015: evaluation of initial surgical versus conservative strategies in patients with asymptomatic severe aortic stenosis (The CURRENT AS registry)

HOW SHOULD I TREAT?

- 58** How should I treat a patient with critical stenosis of a bifurcation of the left main coronary artery with an acute angulation between the left main artery and the left circumflex artery?
- 65** How should I treat a percutaneous posteromedial mitral periprosthetic paravalvular leak closure in a bioprosthesis with no radiopaque ring?